ERBB2 and breast carcinoma: Accompanied with cell invasion data as well as the deregulation of AKT, mTOR and HER2, which play an important role in carcinogenesis (refs), we suggest that the combination therapy of TZ and BMS-202 may serve as an inhibitor of HER2+ breast cancer cell invasion.